review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Günther Deuschl | Q30501407 |
Torge Rempe | Q59678951 | ||
Thorsten Bartsch | Q61042082 | ||
Olav Jansen | Q88007239 | ||
P2093 | author name string | Christian Wüthrich | |
Wolfgang Brück | |||
Igor J Koralnik | |||
Frank Leypoldt | |||
Arne Wrede | |||
Ortwin Adams | |||
Axel Rohr | |||
P2860 | cites work | Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis | Q28275399 |
The human polyomavirus, JCV, uses serotonin receptors to infect cells | Q28294207 | ||
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate | Q28388243 | ||
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 | ||
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 | ||
The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy | Q30689194 | ||
Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). | Q30787775 | ||
Seizures and their outcome in progressive multifocal leukoencephalopathy | Q31030491 | ||
Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells | Q31902271 | ||
Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression | Q33510514 | ||
Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report | Q33581135 | ||
Drug-induced lymphopenia: focus on CD4+ and CD8+ cells | Q33717048 | ||
Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy | Q34041795 | ||
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis | Q34300614 | ||
Progressive multifocal leukoencephalopathy: why gray and white matter | Q34307762 | ||
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy | Q34324861 | ||
A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. | Q34328813 | ||
Persistence and pathogenesis of the neurotropic polyomavirus JC | Q34459843 | ||
Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate | Q34734724 | ||
Asymptomatic reactivation of JC virus in patients treated with natalizumab | Q34801034 | ||
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. | Q34803324 | ||
Determinants of survival in progressive multifocal leukoencephalopathy | Q35012056 | ||
JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals | Q35194420 | ||
Progressive multifocal leukoencephalopathy associated with isolated CD8+ T-lymphocyte deficiency mimicking tumefactive MS | Q35476415 | ||
Dimethyl fumarate associated lymphopenia in clinical practice. | Q35588830 | ||
Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy | Q35590449 | ||
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. | Q35609239 | ||
Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy | Q35634870 | ||
Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy | Q35785136 | ||
Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients | Q36193502 | ||
Metabolic profile of PML lesions in patients with and without IRIS: an observational study | Q36198630 | ||
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? | Q36544721 | ||
Idiopathic CD4 Lymphocytopenia: Spectrum of opportunistic infections, malignancies, and autoimmune diseases | Q37073035 | ||
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes | Q37135539 | ||
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients | Q37206687 | ||
Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. | Q37492573 | ||
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing. | Q38068499 | ||
Identification and characterization of mefloquine efficacy against JC virus in vitro | Q39877627 | ||
Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome | Q41906877 | ||
Finger pointing to JC virus: a tale of two indexes | Q42560354 | ||
Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis | Q42972411 | ||
Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis | Q43187497 | ||
Dimethylfumarate is a potent inducer of apoptosis in human T cells | Q44693135 | ||
Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy | Q45386676 | ||
JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy | Q45751488 | ||
Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. | Q51846870 | ||
Diagnosis of central nervous system complications in HIV-infected patients | Q58292184 | ||
Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies | Q60962707 | ||
Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis | Q74501564 | ||
Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy | Q77336908 | ||
Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera | Q80732978 | ||
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy | Q84114256 | ||
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk | Q85635552 | ||
PML in a patient treated with fumaric acid | Q86649822 | ||
PML in a patient treated with dimethyl fumarate from a compounding pharmacy | Q86649825 | ||
PML in a patient without severe lymphocytopenia receiving dimethyl fumarate | Q87077624 | ||
PML in a patient with lymphocytopenia treated with dimethyl fumarate | Q87077628 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | patient | Q181600 |
P304 | page(s) | 501-514 | |
P577 | publication date | 2015-10-01 | |
P1433 | published in | Annals of Neurology | Q564414 |
P1476 | title | Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate | |
P478 | volume | 78 |